Most cancer deaths are ascribed to recurrent diseases that are resistant to conventional chemotherapy, targeted therapy, or immunotherapy. Transcriptional reprogramming is one of the reasons for treatment failure. New therapeutic strategies are urgently needed to target transcriptional reprogramming and enhance drug sensitivity. However, the molecular mechanisms underlying the transcriptional reprogramming in cancer recurrence remain elusive and thus substantially hinder the development of more effective therapies against recurrent disease. In particular, it is unclear how different therapeutic interventions drive transcriptional reprogramming in a context-dependent manner. The upstream signaling pathways and tumor microenvironmental factors that promote the transcriptional reprogramming are not clear. A better understanding of the transcriptional reprogramming network and mechanisms in cancer recurrence is urgently needed to revolutionize the treatment options for patients with recurrent disease and improve clinical outcomes.

In this Research Topic, we aim to collect Original Research, Reviews, and Opinions focusing on the recent advances in transcriptional reprogramming regulation in cancer recurrence. Topics of interest include, but are not limited to:

1. Characterization of transcriptional and epigenetic reprogramming in cancer recurrence.
2. The role of tissue-specific transcription factors in cancer metastasis.
3. How metastatic cancer cells, with original-tissue specificity, adapt to the environment and colonize a distant tissue.
4. The role of epigenetic landscapes’ reorganization in metastatic cancer cells, and impacts of the potential original-to-distant tissue transition in different cancer types.
5. Ligand-receptor interaction and its downstream signaling that drives transcriptional reprogramming in recurrent tumors.
6. Impact of therapy-induced or distal microenvironment-induced stress responses on transcriptional reprogramming in cancer recurrence.
7. Therapeutic strategy to target transcriptional reprogramming.

Please note:

1. Submissions consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.

2. Research focused on proteomic and metabolomic investigation will not be accepted in the Cancer Genetics section of Frontiers in Oncology

Submit your idea

Impact

Frontiers in Oncology

Participating Journals

Impact